Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

overall survival was 9.7 months and that 12 of the 41 evaluable patients are currently alive. No incidences of rash were noted and results were reported to be comparable to intense chemotherapy and radiotherapy. Quality of life was reported as excellent when compared with intensive chemotherapy. Current and planned studies will expand the use of nimotuzumab from the pediatric population to adults with high grade brain tumors.

"Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth

factor receptor (EGFR) monoclonal antibody (MAb), in patients with

unresectable squamous cell carcinoma of the head and neck (SCCHN): A

SENDO Foundation study" (Abstract number 6070): Ten patients with advanced SCCHN, unsuitable for chemo-radiotherapy, were enrolled in a single center phase Ib clinical trial, where they received eight weekly infusions of nimotuzumab at two dose levels: 200mg and 400mg. Paired biopsies were taken from skin and primary tumors, before and 1 week after first infusion.

Nimotuzumab was well tolerated and there was no evidence of skin rash in any of the treated patients. Objective Response was achieved in 80% of patients (2 Complete Responses, 6 Partial Responses) and median survival time was 7.2 months. Results also demonstrated that after a short period of exposure, nimotuzumab as a single agent inhibited EGFR phosphorylation and this was accompanied by a trend towards molecular downstream effects consistent with the expected biological effects of EGFR targeting. The absence of inflammatory skin reaction might be linked to the lack of skin toxicity by the drug.

In addition, YM BioSciences presented data, described in a separate press release issued today by the Company, based on the following poster:
"Preliminary results of an escalating dose phase I clinical trial of the

anti-EGFR monoclonal antibody nimotuzumab in combination with external

radiotherapy in patients diagnosed
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... Texas (PRWEB) April 23, 2015 ReliantHeart's ... True Flow (blood flow through the device) in real ... by Numerex, the world’s leading provider of Machine to ... , True Flow via VADLink.com can ... there is any drop in flow below a minimum ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... 2015 2015 HIMSS Annual Conference & ... of the 9th annual Venture+ Forum pitch competition for ... selected to deliver live pitch presentations to a panel ... HIMSS15 held last week in Chicago ... professionals and 1,200 exhibiting companies from around the world, ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 3
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Stat1, which is involved in cellular immune signaling, scientists have ... efficient. This old protein with a new twist may eventually ... , Stat1 is involved in immune responses that are initiated ... the cells of the immune system in response to challenges ...
... have demonstrated that the brains of alcoholics are ... brains. Symposium speakers at the October 2004 Congress ... Alcoholism in Mannheim, Germany reviewed what is known ... alcohol-related brain shrinkage. Proceedings are published in the ...
... require accurate transmission. Big genes are especially challenging ... lie between long stretches of non-coding elements (introns). ... pasted together to form a template for proteins ... can reduce the expression of a functional protein ...
Cached Biology News:Engineered molecule amplifies body's immune response 2Engineered molecule amplifies body's immune response 3Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Carnegie Mellon University research reveals how cells process large genes 2Carnegie Mellon University research reveals how cells process large genes 3